Published in J Hepatol on December 01, 2000
Liver enzyme alteration: a guide for clinicians. CMAJ (2005) 3.42
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol (2005) 1.71
Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol (2008) 1.69
CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol (2006) 1.25
Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol (2008) 1.18
Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci (2005) 1.12
Persistent hypertransaminasemia in asymptomatic children: a stepwise approach. World J Gastroenterol (2013) 1.06
Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies. BMJ Case Rep (2009) 1.05
Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol (2007) 1.03
Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis? J Clin Transl Hepatol (2013) 0.96
Assessing causality in drug-induced liver injury. J Hepatol (2000) 0.83
Acute drug induced hepatitis secondary to a weight loss product purchased over the internet. Nutr J (2007) 0.80
[Morphology of drug induced liver damage]. Pathologe (2006) 0.76
Drug-induced Liver Injury. US Gastroenterol Hepatol Rev (2010) 0.76
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Monitoring adverse reactions to drugs. Br Med J (1977) 4.41
A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry (1990) 3.74
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol (1998) 3.57
Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) (1985) 2.97
Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol (1999) 2.78
Comprehensive clinical drug information service: first year's experience. Br Med J (1977) 2.77
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet (1995) 2.64
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut (2005) 2.62
The failings of NICE. Reply from chairman of NICE. BMJ (2001) 2.55
Activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet (1979) 2.54
Clinical pharmacology in the National Health Service. J R Soc Med (1978) 2.54
Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol (1992) 2.51
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
The role of the pharmaceutical industry in postgraduate medical education. Br J Clin Pharmacol (1977) 2.45
Clinical pharmacology clinics in general practice. Br Med J (1977) 2.28
Doctors and the drug makers. Lancet (1984) 2.09
Extending the role of the community pharmacist. BMJ (1991) 2.05
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ (1997) 1.96
Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol (1979) 1.95
Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology (1997) 1.94
Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J (1980) 1.87
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology (1998) 1.84
Review of yellow cards--1986 and 1987. Br Med J (Clin Res Ed) (1988) 1.81
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
[Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands]. Ned Tijdschr Geneeskd (1995) 1.79
Letter: How do doctors learn about drugs? Lancet (1975) 1.78
Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol (1977) 1.76
Psoriasis and cancer. Br Med J (1979) 1.71
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1987) 1.69
Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut (2000) 1.68
New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol (1998) 1.67
Drug information centres: a clinical pharmacologist's view. Proc R Soc Med (1977) 1.66
Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med (1985) 1.65
Predicting patients' warfarin requirements. Lancet (1977) 1.61
Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) (1984) 1.57
Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology (2005) 1.50
Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) (1987) 1.46
Low prevalence of hepatitis B in mental handicap hospital. Lancet (1989) 1.45
Hospital prescribing and usage of hypnotics and anxiolytics. Br J Clin Pharmacol (1991) 1.44
Geographical differences in adverse drug reaction reporting rates in the Northern Region. Br J Clin Pharmacol (1991) 1.43
The natural history of histologically proved drug induced liver disease. Gut (1999) 1.43
Spontaneous periodic hypothermia: diencephalic epilepsy. Br Med J (1973) 1.39
Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. Q J Med (1986) 1.39
Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol (1998) 1.39
Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol (1979) 1.36
Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J (Clin Res Ed) (1985) 1.36
Clinical pharmacology. Adverse reactions to drugs. Br Med J (Clin Res Ed) (1981) 1.35
A method for obtaining saliva samples from infants and young children. Br J Clin Pharmacol (1978) 1.32
Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ (1999) 1.31
Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly. J Antimicrob Chemother (2000) 1.29
Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med (2001) 1.26
Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol (1979) 1.26
The effects of salicylate on temperature regulation in the rabbit. J Physiol (1970) 1.24
Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol (2001) 1.24
The activity of aryl hydrocarbon hydroxylase in adult human skin. Br J Clin Pharmacol (1979) 1.22
Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol. Eur J Clin Pharmacol (1974) 1.22
Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry (1984) 1.22
The association of age and frailty with paracetamol conjugation in man. Age Ageing (1990) 1.22
Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol (1999) 1.20
Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol (1975) 1.20
Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut (2005) 1.19
Efficacy and pharmacokinetics of aspirin in post-operative dental pain. Br J Clin Pharmacol (1982) 1.18
Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol (1996) 1.17
Who are the frail elderly? Q J Med (1988) 1.17
Benzodiazepines. Br Med J (1977) 1.15
Family study of antipyrine clearance. Br Med J (Clin Res Ed) (1982) 1.15
Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth (1976) 1.15
Decreased epidermal aryl hydrocarbon hydroxylase and localized pustular psoriasis. Br J Dermatol (1980) 1.14
Transferable pyrogen in human experimental fever. Clin Sci (1971) 1.13
Pharmacokinetics of parenteral paracetamol and its analgesic effects in post-operative dental pain. Eur J Clin Pharmacol (1981) 1.12
Placebo-controlled study of phenobarbitone and phenytoin in the prophylaxis of febrile convulsions. Lancet (1981) 1.11
The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut (2007) 1.11
Aryl hydrocarbon hydroxylase activity and psoriasis. Biochem Pharmacol (1983) 1.11
The effects of astemizole on histamine-induced weal and flare. Eur J Clin Pharmacol (1983) 1.10
Hepatic drug acetylation and oxidation: effects of aging in man. Br Med J (1977) 1.09
A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry (1982) 1.09
Predicting the dose of warfarin for therapeutic anticoagulation. Thromb Haemost (1982) 1.09
Acute thermoregulatory and cardiovascular effects of 6-hydroxydopamine administered centrally in rabbits and cats. Br J Pharmacol (1972) 1.09
Panic and the pill. Nature (1996) 1.08
The role of the clinical pharmacologist in district general hospitals. Br J Clin Pharmacol (1979) 1.07
The lancet - saturday 26 June 1982. Lancet (1982) 1.07
Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis (2007) 1.07
Pyrexia in renal carcinoma. Lancet (1970) 1.06
Influence of the duration of experimental fever on salicylate antipyresis in the rabbit. Br J Pharmacol (1971) 1.03
The effect of adrenaline in lignocaine anaesthetic solutions on plasma potassium in healthy volunteers. Eur J Clin Pharmacol (1987) 1.03
Plasma concentrations of sodium valproate: their clinical value. Ann Neurol (1983) 1.02
Using the Adverse Reactions Register to study the effects of age and sex on adverse drug reactions. Stat Med (1988) 1.01
Plasma aspirin esterase: the influence of old age and frailty. Age Ageing (1989) 1.01
The effects of intradermal bradykinin are potentiated by angiotensin converting enzyme inhibitors in hypertensive patients. Br J Clin Pharmacol (1989) 1.00
The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics (1998) 1.00
Steady-state plasma concentrations of alprenolol in man. Eur J Clin Pharmacol (1974) 1.00
Hypothalamic endogenous noradrenaline and thermoregulation in the cat and rabbit. J Physiol (1972) 0.99